Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias W Beckmann

Showing results (561-570 of 799) with videos related to

Pageof 80
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 21, 2022
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registryVolkmar Müller, Alexander Hein, Andreas D Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT RegistryAndreas D Hartkopf, Christina B Walter, Hans-Christian Kolberg, et al.
Geburtshilfe Und Frauenheilkunde|August 29, 2017
Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer RegistryMarkus Wallwiener, Felix Heindl, Sara Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|November 5, 2019
Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018)Hans-Georg Schnürch, Sven Ackermann, Celine D Alt-Radtke, et al.
Cancers|October 21, 2020
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with PertuzumabLaura L Michel, Andreas D Hartkopf, Peter A Fasching, et al.
Geburtshilfe Und Frauenheilkunde|December 2, 2020
Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab EmtansineElena Laakmann, Julius Emons, Florin-Andrei Taran, et al.
Cancers|December 23, 2018
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer RegistryMichael P Lux, Naiba Nabieva, Andreas D Hartkopf, et al.
Breast Cancer Research and Treatment|September 26, 2014
Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studiesJessica Salmen, Julia Neugebauer, Peter A Fasching, et al.
Breast (Edinburgh, Scotland)|November 4, 2017
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registryAndreas D Hartkopf, Jens Huober, Bernhard Volz, et al.
Cancers|July 20, 2021
Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment SurveillanceHeike Hoyer, Grit Mehlhorn, Cornelia Scheungraber, et al.
Pageof 80

Showing results (561-570 of 799) with videos related to

Sort By:
Pageof 80
European Journal of Cancer (Oxford, England : 1990)|June 21, 2022
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registryVolkmar Müller, Alexander Hein, Andreas D Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT RegistryAndreas D Hartkopf, Christina B Walter, Hans-Christian Kolberg, et al.
Geburtshilfe Und Frauenheilkunde|August 29, 2017
Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer RegistryMarkus Wallwiener, Felix Heindl, Sara Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|November 5, 2019
Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018)Hans-Georg Schnürch, Sven Ackermann, Celine D Alt-Radtke, et al.
Cancers|October 21, 2020
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with PertuzumabLaura L Michel, Andreas D Hartkopf, Peter A Fasching, et al.
Geburtshilfe Und Frauenheilkunde|December 2, 2020
Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab EmtansineElena Laakmann, Julius Emons, Florin-Andrei Taran, et al.
Cancers|December 23, 2018
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer RegistryMichael P Lux, Naiba Nabieva, Andreas D Hartkopf, et al.
Breast Cancer Research and Treatment|September 26, 2014
Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studiesJessica Salmen, Julia Neugebauer, Peter A Fasching, et al.
Breast (Edinburgh, Scotland)|November 4, 2017
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registryAndreas D Hartkopf, Jens Huober, Bernhard Volz, et al.
Cancers|July 20, 2021
Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment SurveillanceHeike Hoyer, Grit Mehlhorn, Cornelia Scheungraber, et al.
Pageof 80